ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
argenx SE

argenx SE (ARGX)

577.89
-8.87
(-1.51%)
577.89
0.27
(0.05%)

개인 투자자를 위한 전문가급 도구.

프리미엄

주요 통계 및 세부정보

가격
577.89
매수가
570.00
매도가
584.00
거래량
297,420
575.41 일간 변동폭 583.16
0.00 52주 범위 0.00
market_cap
전일 종가
586.76
개장가
580.82
최근 거래 시간
10
@
579
마지막 거래 시간
재정 규모
US$ 172,624,692
VWAP
580.4071
평균 볼륨(3m)
-
발행 주식
60,990,857
배당수익률
-
주가수익률
42.94
주당순이익(EPS)
13.66
매출
2.25B
순이익
833.04M

argenx SE 정보

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, AR... argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland. 더 보기

섹터
Coml Physical, Biologcl Resh
산업
Coml Physical, Biologcl Resh
웹사이트
본부
Amsterdam, North Holland, Nld
설립됨
-
argenx SE is listed in the Coml Physical, Biologcl Resh sector of the 나스닥 with ticker ARGX. The last closing price for argenx was US$586.76. Over the last year, argenx shares have traded in a share price range of US$ 0.00 to US$ 0.00.

argenx currently has 60,990,857 shares in issue. The market capitalisation of argenx is US$35.79 billion. argenx has a price to earnings ratio (PE ratio) of 42.94.

argenx (ARGX) 옵션 플로우 요약

전체 흐름

약세

순 프리미엄

-40k

Calls / Puts

0.00%

매수 / 매도

100.00%

OTM / ITM

100.00%

Sweeps 비율

0.00%

ARGX 최신 뉴스

기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

ARGX - Frequently Asked Questions (FAQ)

What is the current argenx share price?
The current share price of argenx is US$ 577.89
How many argenx shares are in issue?
argenx has 60,990,857 shares in issue
What is the market cap of argenx?
The market capitalisation of argenx is USD 35.79B
What is the 1 year trading range for argenx share price?
argenx has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of argenx?
The price to earnings ratio of argenx is 42.94
What is the cash to sales ratio of argenx?
The cash to sales ratio of argenx is 15.91
What is the reporting currency for argenx?
argenx reports financial results in USD
What is the latest annual turnover for argenx?
The latest annual turnover of argenx is USD 2.25B
What is the latest annual profit for argenx?
The latest annual profit of argenx is USD 833.04M
What is the registered address of argenx?
The registered address for argenx is LAARDERHOOGTWEG 25, AMSTERDAM, NORTH HOLLAND, 1101 EB
What is the argenx website address?
The website address for argenx is www.argenx.com
Which industry sector does argenx operate in?
argenx operates in the COML PHYSICAL, BIOLOGCL RESH sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
RBNERobin Energy Ltd
US$ 13.85
(313.43%)
101.81M
OPOceanPal Inc
US$ 1.63
(125.45%)
80.28M
LGHLWLion Group Holding Ltd
US$ 0.0052
(116.67%)
6.87M
NEONNeonode Inc
US$ 16.83
(68.47%)
4.78M
ICONIcon Energy Corporation
US$ 2.90
(62.01%)
59.04M
SBETSharpLink Gaming Inc
US$ 9.2275
(-71.63%)
41.92M
AIHSSenmiao Technology Ltd
US$ 0.381
(-63.01%)
16.8M
CHSNChanson International Holding
US$ 0.22
(-60.00%)
15.15M
KWMK Wave Media Ltd
US$ 2.91
(-50.43%)
2.59M
JZXNJiuzi Holdings Inc
US$ 1.56
(-46.39%)
2.24M
HCTIHealthcare Triangle Inc
US$ 0.0201
(-33.00%)
856.89M
GNLNGreenlane Holdings Inc
US$ 0.0101
(-34.42%)
792.34M
CGBSCrown LNG Holdings Ltd
US$ 0.1104
(31.43%)
788.42M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 12.655
(3.81%)
246.13M
NVDANVIDIA Corporation
US$ 141.97
(-2.09%)
180.81M

ARGX Discussion

게시물 보기
Monksdream Monksdream 7 월 전
ARGX new 52+week high
👍️0
Monksdream Monksdream 9 월 전
ARGX over $500

👍️0
Monksdream Monksdream 10 월 전
ARGX new 52 week high
👍️0
Monksdream Monksdream 11 월 전
ARGX under $500
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 4 년 전
Looking good
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 4 년 전
Progress in Sub-cu Efgartigimod was discussed in some detail yesterday during the Halozyme conference call.
👍️0
jonny_red jonny_red 6 년 전
3 Penny Stocks To Buy Or Sell Before Friday? 1 Up 110% This Quarter

$CLSD $AR $AGRX

https://www.transparenttraders.me/2019/11/3-penny-stocks-to-buy-or-sell-before.html
👍️0
ClayTrader ClayTrader 7 년 전
* * $AGRX Video Chart 11-01-18 * *

Link to Video - click here to watch the technical chart video

👍️0
riche riche 7 년 전
Efgartigimod is a first-in-class antibody fragment designed for the treatment of patients with severe autoimmune diseases associated with high levels of pathogenic immunoglobulin G, or IgG, antibodies for which few innovative biologic treatments have been approved and severe unmet medical need exists. Efgartigimod has been created to degrade circulating disease-causing autoimmune antibodies and has potential in many large and orphan indications: multiple sclerosis, immune thrombocytopenia, systemic lupus erythematosus, myasthenia gravis and skin blistering

👍️0
riche riche 7 년 전
Year targets !!

KBC 87 euro Wedbush 121 $ = 104 euro Piper Jaffray 154 $ = 132 euro JMP Securities 150 $ = 129 euro Stiffel 139 $ = 119,50 euro Nomura 161 $ = 138,40 Kempen en Co 140 euro

STRONG BUY !!!
👍️0
riche riche 7 년 전
1-4 Dec 2018: Efgartigimod full Phase II ITP data, ARGX-110 full Phase I AML dose-escalation data, ARGX-110 full Phase II CTCL data YE 2018: launch of Phase III MG trial with Efgartigimod.

👍️0
riche riche 7 년 전
https://thefly.com/landingPageNews.php?id=2794139 Argenx data concerns over rescue therapy unfounded, says Piper Jaffray Argenx last week reported positive Phase II immune thrombocytopenia data on efgartigimod showing clean safety and clear efficacy, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. He points out that twelve, or 46%, efgartigimod-treated patients achieved clinically meaningful platelet improvement. The analyst views concern over rescue therapy and bleeding events as unfounded and reiterates an Overweight rating on Argenx shares with a $154 price target. Bioscience liked last!Lampi, Bioscience waardeerde(-n)

👍️0
riche riche 7 년 전
Sorry, theWhat a JOKE!...SOLD 3.5M shares at $86.50 a share...BUT...also gave each share an option to buy a share at equivalent of $ .15 a share.... therefore 7MM shares at equivalent $43.25 a share...THIS IS GOING DOWN!!! "closing of its public offering in the United States and an offering in Europe only to qualified investors (within the meaning of Directive 2003/71/EC, as amended) (the Offering) of 3,475,000 American Depositary Shares (ADSs) at a price to the public of $86.50 per ADS, for gross proceeds of approximately $300.6 million, before deducting underwriting discounts and commissions and offering expenses payable by argenx.Each of the ADSs offered represents the right to receive one ordinary share, nominal value of #$%$0.10 per share. All of the ADSs in the Offering were offered by argenx." Ik heb de vraag gisterenavond voor gelegd bij ARgen-X Hieronder het bericht zoals het uitgelegd moet worden . Gegeven door niet minder dan Joke Comijn dir . IR ARgenx Dag Bioscience De nominale waarde is de waarde van het aandeel zoals die staat beschreven in de statuten van een NV. De nominale waarde heeft niets te maken met de werkelijke waarde van een aandeel, en ook niet met de discount van de transactie. Dit is duidelijk te zien op de balans van de meeste (beursgenoteerde) bedrijven waar je onder de equity zowel share capital (de nominale waarde van alle aandelen) als share premium (de betaalde waarde voor de aandelen bovenop de nominale waarde) terugvindt. https://nl.wikipedia.org/wiki/Nominale_waarde Bijkomend wil ik nog laten weten dat de inschrijvers op ADSen geen recht hebben op een ‘bijkomend’ aandeel: bij de kapitaalverhoging zijn de aandelen gecreëerd, die vervolgens in bewaring zijn gegeven, die op haar beurt per in bewaring gegeven aandeel een certificaat (American Depository Security) heeft uitgegeven aan de aandeelhouders die hun argenx aandelen op Nasdaq verhandelen. De reden hiervoor is dat er juridische belemmeringen zijn om aandelen van een Nederlandse vennootschap rechtstreeks op Nasdaq te verhandelen. Met vriendelijke groeten, Joke DUS de aandelen zijn gekocht voor $ 86,50 en niet voor minder !!! ( geen extra korting . Daar zitten we nu dus al 11 $ onder .

Lees meer op: https://beursig.com/forum/viewtopic.php?f=4&t=1804&start=2050 voor meer informatie answer is in Dutch.
👍️0
riche riche 7 년 전
https://clinicaltrials.gov/ct2/show/NCT03102593
👍️0
Justfactsmam Justfactsmam 7 년 전
I don't think so...TOXIC FINANCING DEAL ....EU private financing deal...just gave away 7MM share at $43.50 a share when was trading over double that last week...

3.5 MM shares sold at $86.50 a share...BUT...also gave each share an option to buy a share at equivalent of $ .15 a share.... therefore 7MM shares at equivalent $43.25 a share...

THIS IS GOING DOWN!!!
👍️0
stocktrademan stocktrademan 7 년 전
ARGX buy 75.10



















normal chart




log chart



👍️0

최근 히스토리

Delayed Upgrade Clock